Empyrean Capital Partners LP Makes New $24.24 Million Investment in Charles River Laboratories International, Inc. $CRL

Empyrean Capital Partners LP bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 121,500 shares of the medical research company’s stock, valued at approximately $24,237,000. Empyrean Capital Partners LP owned 0.25% of Charles River Laboratories International at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in CRL. Massachusetts Financial Services Co. MA acquired a new stake in Charles River Laboratories International in the fourth quarter worth approximately $176,478,000. Victory Capital Management Inc. lifted its position in shares of Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares during the last quarter. National Bank of Canada FI lifted its position in shares of Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $96,765,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $182.97 on Thursday. The company’s fifty day moving average is $174.31 and its two-hundred day moving average is $182.64. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 12-month low of $143.06 and a 12-month high of $228.88. The company has a market cap of $8.81 billion, a P/E ratio of -48.66, a price-to-earnings-growth ratio of 2.11 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period in the previous year, the business earned $2.34 EPS. The company’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Mizuho set a $192.00 price objective on Charles River Laboratories International in a research report on Friday, May 8th. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price objective for the company from $167.00 to $219.00 in a research report on Friday, May 29th. UBS Group increased their price objective on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Weiss Ratings downgraded Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.